Fig. 2From: Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trialWaterfall plot of overall response of the target lesions measured by RECIST 1.0Back to article page